Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Share-based Compensation: 2023-2025

Historic Share-based Compensation for Inhibrx Biosciences (INBX) over the last 2 years, with Sep 2025 value amounting to $3.2 million.

  • Inhibrx Biosciences' Share-based Compensation rose 7.08% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.4 million, marking a year-over-year decrease of 81.64%. This contributed to the annual value of $58.5 million for FY2024, which is 135.52% up from last year.
  • As of Q3 2025, Inhibrx Biosciences' Share-based Compensation stood at $3.2 million, which was up 14.62% from $2.8 million recorded in Q2 2025.
  • Over the past 5 years, Inhibrx Biosciences' Share-based Compensation peaked at $46.2 million during Q2 2024, and registered a low of $2.5 million during Q1 2025.
  • Its 3-year average for Share-based Compensation is $8.9 million, with a median of $3.2 million in 2025.
  • Within the past 5 years, the most significant YoY rise in Inhibrx Biosciences' Share-based Compensation was 7.08% (2025), while the steepest drop was 94.00% (2025).
  • Quarterly analysis of 3 years shows Inhibrx Biosciences' Share-based Compensation stood at $6.4 million in 2023, then tumbled by 53.60% to $3.0 million in 2024, then climbed by 7.08% to $3.2 million in 2025.
  • Its Share-based Compensation stands at $3.2 million for Q3 2025, versus $2.8 million for Q2 2025 and $2.5 million for Q1 2025.